Transaction DateRecipientSharesTypePriceValue
16th September 2020Susan Rodriguez6,087Open or private sale$6.11$37,164.18
16th September 2020Jeffrey W Jacobs10,000Open or private sale$6.05$60,500.00
15th September 2020Michael Raab106,337Open or private sale$5.61$596,284.73
15th September 2020Elizabeth A Grammer28,810Open or private sale$5.37$154,574.29
15th September 2020Jeffrey W Jacobs40,804Open or private sale$5.53$225,588.99
15th September 2020Robert Blanks34,685Open or private sale$5.45$189,182.40
15th September 2020David P. Rosenbaum34,656Open or private sale$5.52$191,301.12
15th September 2020David P. Rosenbaum3,470Open or private sale$5.51$19,131.15
15th September 2020Justin A Renz3,714Open or private sale$5.49$20,372.78
14th September 2020Scott D Sandell2,000,000Other acquisition or disposition$0.00
Ardelyx logo

Ardelyx, Inc. focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development.

Ticker: ARDX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1437402
Employees: 88
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags